論文 - 海北 幸一
-
Ishii M., Kaikita K., Sato K., Tanaka T., Sugamura K., Sakamoto K., Izumiya Y., Yamamoto E., Tsujita K., Yamamuro M., Kojima S., Soejima H., Hokimoto S., Matsui K., Ogawa H.
Journal of the American College of Cardiology 66 ( 10 ) 1105 - 1115 2015年9月
担当区分：責任著者 記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of the American College of Cardiology
Background Coronary artery spasm contributes to the pathogenesis of variant angina and ischemic heart disease and may play a role in the progression of atherosclerosis. It is unclear whether the location of spasm is related to outcome. Objectives This study compared the clinical features and prognosis of patients with coronary spasm at the site of significant atherosclerotic stenosis with patients with spasm at sites without stenosis or nonsignificant stenosis. Methods This was a retrospective, observational study of 1,877 consecutive patients with typical or atypical angina-like chest pain undergoing acetylcholine (ACh)-provocation testing. A total of 1,760 patients were eligible for analysis. ACh-provoked coronary spasm and significant organic stenosis were observed in 873 and 358 patients, respectively. Results In patients with significant atherosclerotic stenosis, ACh-positive patients (n = 233) were younger and without diabetes mellitus compared with nonspasm patients (n = 125). In patients without organic stenosis, ACh-positive patients (n = 640) were older, had dyslipidemia, and were more likely to have a family history of ischemic heart disease than nonspasm patients (n = 762). Multiple logistic regression analysis identified ST-segment elevation during anginal attacks, organic stenosis of the left anterior descending artery, and multivessel spasm as correlates of spasm at sites of significant organic stenosis (n = 192). Multivariate analysis identified ACh-provoked spasm at the site of significant stenosis and use of nitrates as the 2 prognostic factors for major adverse cardiac events. Conclusions The clinical features and prognosis of patients with ACh-provoked coronary spasm were different when it occurred at the site of significant atherosclerotic stenosis compared with patients with spasm elsewhere. Both spasm at the site of significant organic stenosis and nitrate use were significant predictors of major adverse cardiac events.
-
Sueta D., Yamamoto E., Tanaka T., Hirata Y., Sakamoto K., Tsujita K., Kojima S., Nishiyama K., Kaikita K., Hokimoto S., Jinnouchi H., Ogawa H.
IJC Heart and Vasculature 8 52 - 54 2015年9月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：IJC Heart and Vasculature
-
Misumi I., Nishida Y., Honda T., Kurokawa H., Yasuda H., Kaikita K., Hokimoto S., Ogawa H.
Internal Medicine 54 ( 17 ) 2197 - 2200 2015年9月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Internal Medicine
A boy with Duchenne muscular dystrophy was admitted to our hospital due to a transient loss of consciousness. Transthoracic echocardiography revealed left ventricular (LV) dilatation and diffuse hypokinesis of the LV wall. The LV wall was thin, and both non-compaction of the LV wall and marked thinning of the posterior LV wall resulting from a lesion were observed. The plasma B-type natriuretic peptide (BNP) level ultimately increased to 7,795 pg/mL, and the patient died of cardiac arrest following ventricular tachycardia. Severe heart failure, a critical condition, and thinning of the LV wall may have contributed to the markedly high plasma BNP level in this case.
-
Novel vascular indices evaluated non-invasively in end-stage renal disease patients on hemodialysis 査読あり
Sueta D, Yamamoto E＊, Hirata Y, Tokitsu T, Sakamoto K, Tsujita K, Kaikita K, Hokimoto S, Sakanashi T
Clinical Trials and Regulatory Science in Cardiology 9 1 - 3 2015年9月
記述言語：英語 掲載種別：研究論文（学術雑誌）
-
Sueta D., Kaikita K., Okamoto N., Arima Y., Ishii M., Ito M., Oimatsu Y., Iwashita S., Takahashi A., Nakamura E., Hokimoto S., Mizuta H., Ogawa H.
International Journal of Cardiology 197 98 - 100 2015年8月
担当区分：責任著者 記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Cardiology
-
Tsujita K., Sugiyama S., Sumida H., Shimomura H., Yamashita T., Yamanaga K., Komura N., Sakamoto K., Oka H., Nakao K., Nakamura S., Ishihara M., Matsui K., Sakaino N., Nakamura N., Yamamoto N., Koide S., Matsumura T., Fujimoto K., Tsunoda R., Morikami Y., Matsuyama K., Oshima S., Kaikita K., Hokimoto S., Ogawa H.
Journal of the American College of Cardiology 66 ( 5 ) 495 - 507 2015年8月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of the American College of Cardiology
Background Despite standard statin therapy, a majority of patients retain a high "residual risk" of cardiovascular events. Objectives The aim of this study was to evaluate the effects of ezetimibe plus atorvastatin versus atorvastatin monotherapy on the lipid profile and coronary atherosclerosis in Japanese patients who underwent percutaneous coronary intervention (PCI). Methods This trial was a prospective, randomized, controlled, multicenter study. Eligible patients who underwent PCI were randomly assigned to atorvastatin alone or atorvastatin plus ezetimibe (10 mg) daily. Atorvastatin was uptitrated with a treatment goal of low-density lipoprotein cholesterol (LDL-C) <70 mg/dl. Serial volumetric intravascular ultrasound was performed at baseline and again at 9 to 12 months to quantify the coronary plaque response in 202 patients. Results The combination of atorvastatin/ezetimibe resulted in lower levels of LDL-C than atorvastatin monotherapy (63.2 ± 16.3 mg/dl vs. 73.3 ± 20.3 mg/dl; p < 0.001). For the absolute change in percent atheroma volume (PAV), the mean difference between the 2 groups (-1.538%; 95% confidence interval [CI]: -3.079% to 0.003%) did not exceed the pre-defined noninferiority margin of 3%, but the absolute change in PAV did show superiority for the dual lipid-lowering strategy (-1.4%; 95% CI: -3.4% to -0.1% vs. -0.3%; 95% CI: -1.9% to 0.9% with atorvastatin alone; p = 0.001). For PAV, a significantly greater percentage of patients who received atorvastatin/ezetimibe showed coronary plaque regression (78% vs. 58%; p = 0.004). Both strategies had acceptable side effect profiles, with a low incidence of laboratory abnormalities and cardiovascular events. Conclusions Compared with standard statin monotherapy, the combination of statin plus ezetimibe showed greater coronary plaque regression, which might be attributed to cholesterol absorption inhibition-induced aggressive lipid lowering. (Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound [PRECISE-IVUS]; NCT01043380)
-
Clinical significance of pulse pressure in patients with coronary artery disease 査読あり
Tokitsu T., Yamamoto E., Hirata Y., Fujisue K., Sueta D., Sugamura K., Sakamoto K., Kaikita K., Hokimoto S., Sugiyama S., Ogawa H.
International Journal of Cardiology 190 ( 1 ) 299 - 301 2015年8月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Cardiology
-
Yamamoto E., Hirata Y., Tokitsu T., Kusaka H., Sakamoto K., Yamamuro M., Kaikita K., Watanabe H., Hokimoto S., Sugiyama S., Maruyama T., Ogawa H.
International Journal of Cardiology 190 ( 1 ) 335 - 337 2015年8月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Cardiology
-
Systolic flow reversal in a case of mid-ventricular obstructive hypertrophic cardiomyopathy 査読あり
Misumi I., Honda T., Kurokawa H., Kubota Y., Ishii M., Sato R., Yamabe H., Yasuda H., Kaikita K., Hokimoto S., Ogawa H.
Internal Medicine 54 ( 14 ) 1765 - 1769 2015年7月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Internal Medicine
A 69-year-old man presented to our hospital with chest pain. Two-dimensional transthoracic echocardiography showed hypertrophy of the left ventricle, mid-ventricular obstruction and an apical aneurysm. Color-flow imaging at the obstruction site on the apical four-chamber view demonstrated systolic flow reversal in addition to a paradoxical jet flow. The systolic flow reversal may have been caused by a decreased apical contractility and pressure during systole.
-
Sueta D., Yamamoto E., Tanaka T., Hirata Y., Sakamoto K., Tsujita K., Kojima S., Nishiyama K., Kaikita K., Hokimoto S., Jinnouchi H., Ogawa H.
International Journal of Cardiology 189 ( 1 ) 244 - 246 2015年6月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Cardiology
-
The pivotal role of a novel biomarker of reactive oxygen species in chronic kidney disease 査読あり
Hirata Y., Yamamoto E., Tokitsu T., Fujisue K., Kurokawa H., Sugamura K., Sakamoto K., Tsujita K., Tanaka T., Kaikita K., Hokimoto S., Sugiyama S., Ogawa H.
Medicine (United States) 94 ( 25 ) e1040 2015年6月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Medicine (United States)
Risk stratification of chronic kidney disease (CKD) is clinically important because such patients are at high risk of cardiovascular events. Although reactive oxygen species (ROS) are reported to be closely associated with the pathophysiology of CKD, there are few useful ROS biomarkers known for CKD patients. Hence, our objectives in this study were to investigate whether serum derivatives of reactive oxygen metabolites (DROM), a novel biomarker of ROS, is involved in the pathophysiology of CKD (case-control study), and is a significant predictor of future cardiovascular events in CKD patients (follow-up study). Patients with suspected coronary artery disease (CAD) were enrolled and underwent coronary angiography. Patients with CKD (estimated glomerular filtration ratio <60mL/min/1.73m 2 and/or proteinuria, n=324) were compared with those without CKD (non-CKD). Serum DROM was measured at stable conditions. A case-control study of the 324 CKD patients and 263 non-CKD patients was conducted after matching risk factors, and a follow-up study of the 324 CKD patients was performed. CKD patients were divided into low- and high-DROM groups using their median value (348 unit; called the Carratelli unit [U.CARR]), and followed until the occurrence of cardiovascular events. DROM levels were significantly higher in risk factors-matched CKD patients than in risk factors-matched non-CKD patients (347.0 [301.8-391.8] U.CARR vs. 338.5 [299.8-384.3] U.CARR, P=0.03). During mean 23±14 months follow-up of 324 CKD patients, 83 cardiovascular events were recorded. Kaplan-Meier analysis demonstrated a higher probability of cardiovascular events in CKD patients with high DROM than in those with low DROM (P<0.001, log-rank test). Multivariate Cox hazard analysis including significant predictors in simple Cox hazard analysis demonstrated that high DROM was a significant and independent predictor of cardiovascular events in CKD patients (hazard ratio: 1.76, 95% confidence interval: 1.10-2.82, P=0.02). In conclusion, serum DROM values were significant and independent predictors of cardiovascular events in CKD patients, indicating that the measurements of DROM might provide clinical benefits for risk stratification of CKD patients.
-
Resonant cardiac chamber with diastolic thrill 査読あり
Kurokawa H., Misumi I., Honda T., Usuku H., Yasuda H., Kaikita K., Hokimoto S., Ogawa H., Nakatsuka D., Tabata M.
Journal of Echocardiography 13 ( 2 ) 69 - 71 2015年6月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Echocardiography
A 70-year-old man with a diastolic Levine V/VI musical murmur came to our department. Doppler color-flow imaging showed eccentric severe aortic regurgitation. M-mode echocardiography demonstrated fluttering of the anterior mitral leaflet and fine tremors at the aortic root. The curved M-mode representation of the myocardial strain rate showed that the basal septum was encoded in a mixture of blue and red spots during diastole, showing massive basal septal vibration. In the present case, the force of the regurgitant flow might have caused vibration of the basal septum, thereby possibly leading to distinct thrill.
-
Arima Y., Hokimoto S., Akasaka T., Mizobe K., Kaikita K., Oniki K., Nakagawa K., Ogawa H.
Journal of Cardiology 65 ( 6 ) 494 - 500 2015年6月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Cardiology
Aim: CYP2C19 polymorphism modulates platelet reactivity in coronary artery disease patients with stent implants. However, the impact of the CYP2C19 genotype on clopidogrel response and clinical outcome has not been fully understood to date. Methods: We enrolled 518 consecutive patients with acute coronary syndrome (ACS) (n = 214) and stable angina (SA) (n = 304). All patients received stent implants followed by dual antiplatelet therapy of aspirin and clopidogrel. We determined CYP2C19 phenotype, measured platelet reactivity, and assessed the risk of cardiovascular events. Results: During a median follow-up of 894 days, the rate of cardiovascular events was higher in patients of the ACS group than the SA group (ACS: 20.1%, SA: 12.5%, p = 0.015). The mean platelet reactivity was significantly higher in the CYP2C19 loss-of-function allele carriers of the two groups (ACS, non-carriers: 3909 ± 1836 AU min, carriers: 4854 ± 1594 AU min, respectively, p < 0.01; SA, 3606 ± 1579 AU min, 4381 ± 1373 AU min, ±SD, p < 0.01). In the ACS group, cardiovascular events were higher in the loss-of-function allele carriers (24.6%) versus non-carriers (11.1%, p< 0.05), but no such difference was noted in the SA group (carriers: 14.8%; non-carriers: 7.9%, p = 0.078). Furthermore, landmark analysis from 30 days did not show differences in ACS group (carriers: 14.8%, non-carriers: 11.1%, p = 0.315). Multivariate Cox proportional hazards analysis identified the presence of loss-of-function allele as an independent predictor of cardiovascular events (hazard ratio, 2.1, 95% CI, 1.194-3.587, p = 0.010). Conclusions: The impact of CYP2C19 loss-of-function gene on clinical outcome is more powerful in early phase of ACS compared with SA.
-
Hokimoto S., Akasaka T., Tabata N., Arima Y., Tsujita K., Sakamoto K., Kaikita K., Morita K., Kumagae N., Yamamoto E., Oniki K., Nakagawa K., Ogawa H.
Thrombosis Research 135 ( 6 ) 1081 - 1086 2015年6月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Thrombosis Research
Objectives The aim of this study was to investigate the effect of CYP2C19 polymorphism and co-therapy with esomeprazole on the antiplatelet efficacy of clopidogrel. Background The antiplatelet efficacy of clopidogrel depends on CYP2C19 polymorphism or the co-administration of some kind of proton pump inhibitor (PPI). Methods CYP2C19 genotype and the residual platelet reactivity (RPR) were measured in 361 coronary heart disease patients (male, mean age 69 yrs), and the risk of cardiovascular events over a 3-month follow-up was assessed to evaluate the impact of co-administration of esomeprazole during dual antiplatelet therapy with aspirin and clopidogrel. Results The values of RPR did not differ between esomeprazole and non-esomeprazole groups (4389 ± 1112 versus 4079 ± 1355 AU · min, P = 0.103). RPR value was higher in intermediate metabolizers (IM) than in extensive metabolizers (EM) (4089 ± 1252 versus 3697 ± 1215 AU · min P = 0.012) and, similarly, higher in poor metabolizers (PM) than in IM (4884 ± 1027 versus 4089 ± 1252 AU · min, P < 0.001). There were no differences in RPR between esomeprazole and non-esomeprazole groups according to CYP2C19 genotype (EM, 3954 ± 1192 versus 3645 ± 1220 AU · min, P = 0.361; IM, 4401 ± 1063 versus 4051 ± 1271 AU · min, P = 0.293; PM, 4917 ± 669 versus 4876 ± 1099 AU · min, P = 0.907, respectively). There was also no difference in clinical outcomes between esomeprazole and non-esomeprazole groups in the three-month follow-up (0% versus 0.92%, P = 0.487). Conclusions These results suggest that concomitant use of esomeprazole with clopidogrel is not associated with reduced antiplatelet efficacy of clopidogrel or increased risk of cardiovascular events, irrespective of CYP2C19 genotype.
-
Hokimoto S., Sakamoto K., Akasaka T., Kaikita K., Honda O., Naruse M., Ogawa H., Arizono K., Fujisawa S., Fukui H., Fukushima J., Hara M., Higuchi S., Honda O., Ikezaki N., Ikezaki S., Imafuji M., Ishimatsu T., Iwashita H., Iwashita Y., Kawabata Y., Kawatomi M., Kimura S., Kodama M., Kugiyama A., Kuwahara K., Mabe K., Machida J., Maehara A., Matsunaga Y., Matsuoka N., Matsushita K., Matsushita K., Migita A., Miyamoto T., Miyanaka T., Mizutari K., Miyamoto Y., Nabekura Y., Motoyama T., Nagano H., Nagayoshi M., Nakamura T., Nakano T., Nakashita K., Nojiri A., Oda T., Otsuka Y., Sakaguchi S., Sakanashi T., Seto Y., Shimada H., Shimomura T., Tajiri M., Tajiri T., Takamiya T., Takeshita M., Terasaki H., Tsuru T., Tsuruta K., Tsuzaki S., Tsukamoto M., Uekihara S., Uemura S., Uchigashima H., Uemura S., Yamada K., Yano S., Yasumoto N., Tazoe N., Nishi K., Hokimoto S., Sakamoto K., Akasaka T., Kaikita K., Ogawa H.
Circulation Journal 79 ( 6 ) 1269 - 1276 2015年5月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Circulation Journal
Background: Cardiovascular disease is a major cause of mortality in hemodialysis patients. The aim was to assess the relationship of various invasive cardiovascular procedures (ICP) to clinical outcome in hemodialysis patients. Methods and Results: A total of 5,813 patients at 76 facilities were on maintenance hemodialysis in Kumamoto Prefecture. Of these, 4,807 patients at 58 institutions were enrolled. Of 4,807 patients, 212 ICP (4.4%) were performed for various cardiovascular diseases in 189 patients (3.9%). ICP included PCI (n=80), endovascular treatment (n=59), radiofrequency catheter ablation (n=8), implantation of permanent pacemaker (n=15) and ICD (n=5), thoracotomy for valvular diseases (n=16), CABG (n=14), bypass surgery for peripheral artery disease (PAD; n=8), and artificial vessel replacement for aneurysm or aortic dissection (n=7). The overall mortality rate was 10.1% (19/189 patients). The mortality rate was highest in patients who underwent ICP for PAD, compared with other ICP (PAD, 18.2%; non-PAD, 6.7%, P=0.017). Infection and PAD were significant predictors of mortality (infection: OR, 8.30; 95% CI: 1.29–65.13, P=0.027; PAD: OR, 3.76; 95% CI: 1.35–10.48, P=0.012). The presence of inflammation/malnutrition factors was associated with high mortality (OR, 15.49; 95% CI: 3.22–74.12, P=0.0006). Conclusions: In this community-based registry study of 4,807 hemodialysis patients, the mortality rate of PAD patients was high despite ICP.
-
Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction 査読あり
Tsujita K., Yamanaga K., Komura N., Sakamoto K., Miyazaki T., Ishii M., Tabata N., Akasaka T., Sueta D., Arima Y., Kojima S., Yamamoto E., Yamamuro M., Tanaka T., Izumiya Y., Tayama S., Nakamura S., Kaikita K., Hokimoto S., Ogawa H.
International Journal of Cardiology 187 ( 1 ) 411 - 413 2015年5月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Cardiology
-
Marume K., Hokimoto S., Tabata N., Akasaka T., Tsujita K., Sakamoto K., Yamamoto E., Yamamuro M., Kaikita K., Oniki K., Nakagawa K., Ogawa H.
International Journal of Cardiology 187 ( 1 ) 231 - 233 2015年5月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Cardiology
-
A case of repetitive and simultaneous stent thromboses 査読あり
Sueta D., Hokimoto S., Enomoto K., Ono T., Tabata T., Kajiwara I., Kaikita K., Saruwatari J., Oniki K., Nakagawa K., Ogawa H.
International Journal of Cardiology 186 210 - 212 2015年5月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：International Journal of Cardiology
-
Misumi I., Honda T., Kusuhara K., Yasuda H., Kaikita K., Hokimoto S., Ogawa H.
Journal of Medical Ultrasonics 42 ( 2 ) 239 - 241 2015年4月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Medical Ultrasonics
We report an increase in E/e′ ratio after treatment of heart failure (HF) in two patients. In case 1, the E/e′ ratio increased from 15 to 18 after treatment of HF. In case 2, the E/e′ ratio also increased from 24 to 35. Although a high E/e′ ratio suggests high pulmonary artery wedge pressure and worsening HF, the ratio may increase after improvement of HF. In the present cases of diastolic dysfunction, the high E wave did not change, but the e′ wave decreased relatively. This report may suggest difficulty in evaluating hemodynamic status based on the E/e′ ratio in patients with diastolic dysfunction.
-
Yamamoto M., Tsujita K., Yamanaga K., Komura N., Sakamoto K., Kojima S., Yamamoto E., Tanaka T., Yamamuro M., Izumiya Y., Nakamura S., Kaikita K., Hokimoto S., Ogawa H.
Journal of Cardiology Cases 11 ( 4 ) 120 - 123 2015年4月
記述言語：英語 掲載種別：研究論文（学術雑誌） 出版者・発行元：Journal of Cardiology Cases
We present a case of ST-segment elevation myocardial infarction in the territory of an anomalous left circumflex coronary artery running through the retroaortic region. In vivo coronary imaging with intravascular ultrasound visualized the usual atherosclerotic change and subsequent plaque rupture and thrombus formation at the culprit lesion. The clarification of pathologic mechanisms underlying the myocardial infarction case could provide information about pathophysiology of atherosclerotic development in anomalous left circumflex coronary artery, and could help in decision-making regarding the management strategy.<. Learning objective: Intravascular ultrasound (IVUS) imaging indicated that ordinary atherosclerosis could develop at retroaortic anomalous course of left circumflex coronary artery (LCX) despite absence of mechanical cause of ischemia. IVUS screening could provide significant information about pathophysiology of atherosclerotic development in anomalous LCX, and could help in decision-making regarding the management strategy. The images and discussion have high educational value for clinical cardiologists alike.>.